Molecula Maxima
Synthetic Biology Platform for Genetic Engineering
Company Overview
Snapshot
Founded in January 2015, Molecula Maxima operates with 1–10 employees. The company is developing a programming environment for genetic engineering, aiming to make synthetic biology accessible to software developers. In March 2016, the company was featured for its high-level bioprogramming language designed for DNA sequences.
Business overview
Molecula Maxima is developing a programming environment for the creation of new genetically modified organisms and drugs. The company's core technology involves a synthetic bioprogramming language and the Cytostudio IDE, which engineers can use to design, debug, compile, and optimize chemically synthesized genes. It serves the synthetic biology field, targeting software developers and engineers within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In March 2016, Molecula Maxima gained industry attention for its high-level bioprogramming language designed for DNA sequences. This highlights the company's early innovation in making complex synthetic biology processes more accessible through a software-centric approach, signaling its potential to streamline genetic engineering and drug discovery workflows for a broader technical audience.
Log in to access full profile ›Company Intelligence Q&A
- What is Molecula Maxima's primary focus?
- Molecula Maxima focuses on developing a programming environment for genetic engineering, enabling the creation of new genetically modified organisms and drugs.
- When was Molecula Maxima founded?
- Molecula Maxima was founded in January 2015.
- What is the core technology offered by Molecula Maxima?
- Molecula Maxima offers a Synthetic bioprogramming language and the Cytostudio IDE, which allows engineers to design, debug, compile, and optimize chemically synthesized genes.
- Which industries does Molecula Maxima serve?
- Molecula Maxima serves the Health Tech & Life Sciences sector, particularly within Pharma & Medical Biotechnology and Drugs Discovery & Development, by making synthetic biology accessible to software developers and engineers.
- What significant recognition did Molecula Maxima receive in 2016?
- In March 2016, Molecula Maxima was recognized for its high-level bioprogramming language designed for DNA sequences, as reported by SynBioBeta.